SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Contreras Ruiz J, Kerdel FA. Tacrolimus (FK-506) In: MillikanLE, ed. Drug Therapy in Dermatology. 1st ed. New York, NY: Marcel Dekkar, Inc; 2004:161170.
  • 2
    Ruzicka T, Bieber T, Schöpf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med. 1997;337:816821.
  • 3
    Toutous-Trellu L, Abraham S, Pechere M, et al. Topical tacrolimus for effective treatment of eosinophilic folliculitis associated with human immunodeficiency virus infection. Arch Dermatol. 2005;141:12031208.
  • 4
    Baldo A, Prizio E, Mansueto G, et al. A case of chronic actinic dermatitis treated with topical tacrolimus. J Dermatolog Treat. 2005;16:245248.
  • 5
    Ginarte M, Toribio J. Vulvar lichen sclerosus successfully treated with topical tacrolimus. Eur J Obstet Gynecol Reprod Biol. 2005;123:123124.
  • 6
    Brill TJ, Elshorst-Schmidt T, Valesky EM, et al. Successful treatment of acrodermatitis continua of Hallopeau with sequential combination of calcipotriol and tacrolimus ointments. Dermatology. 2005;211:351355.
  • 7
    Mackelfresh J, Soon S, Arbiser JL. Combination therapy of doxycycline and topical tacrolimus for venous ulcers. Arch Dermatol. 2005;141:14761477.
  • 8
    Moreno-Arias GA, Camps-Fresneda A, Llaberia C, et al. Plasma cell balanitis treated with tacrolimus 0.1%. Br J Dermatol. 2005;153:12041206.
  • 9
    Mitsui T, Kuroda Y, Kunishige M, et al. Successful treatment with tacrolimus in a case of refractory dermatomyositis. Intern Med. 2005;44:11971199.
  • 10
    Shichinohe R, Shibaki A, Nishie W, et al. Successful treatment of severe recalcitrant erosive oral lichen planus with topical tacrolimus. J Eur Acad Dermatol Venereol. 2006;20:6668.
  • 11
    Rubegni P, Poggiali S, Sbano P, et al. A case of Darier's disease successfully treated with topical tacrolimus. J Eur Acad Dermatol Venereol. 2006;20:8487.
  • 12
    Rocha Paris F, Fidalgo A, Baptista J, et al. Topical tacrolimus in Hailey-Hailey disease. Int J Tissue React. 2005;27:151154.
  • 13
    Cancer risk with topical pimecrolimus and tacrolimus. Prescrire Int. 2005;14:223.
  • 14
    Becker JC, Houben R, Vetter CS, et al. The carcinogenic potential of tacrolimus ointment beyond immune suppression: a hypothesis creating case report. BMC Cancer. 2006;6:7.
  • 15
    Kino T, Hatanaka H, Miyata S, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo). 1987;40:12561265.
  • 16
    Sawada S, Suzuki G, Kawase Y, et al. Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation. J Immunol. 1987;139:17971803.
  • 17
    Lawrence ID. Tacrolimus (FK506): experience in dermatology. Dermatologic Ther. 1998;5:7484.
  • 18
    Beck LA. The efficacy and safety of tacrolimus ointment: a clinical review. J Am Acad Dermatol. 2005;53:S165S170.
  • 19
    Meingassner J, Stütz A. Immunosuppressive macrolides of the type FK506: a novel class of topical agents for treatment of skin diseases? J Invest Dermatol. 1992;98:851855.
  • 20
    Lauerma AI, Stein BD, Homey B, et al. Topical tacrolimus (FK506): percutaneous absorption and effect on allergic and irritant contact dermatitis. J Invest Dermatol. 1993;110:491.
  • 21
    Lauerma A, Surber C, Maibach HI. Absorption of topical tacrolimus (FK506) in vitro through human skin: comparison with cyclosporin A. Skin Pharmacol. 1997;10:230234.
  • 22
    Reitamo S, Rissanen J, Remitz A, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol. 1998;111:396398.
  • 23
    Hooks M. Tacrolimus, a new immunosuppressant: a review of the literature. Ann Pharmacother. 1994;28:501511.
  • 24
    Venkataramanan R, Jain A, Warty VS, et al. Pharmacokinetics of FK506 in transplant patients. Transplant Proc. 1991;23:27362740.
  • 25
    Ruzicka T, Assmann T, Homey B. Tacrolimus: the drug for the turn of the millennium? Arch Dermatol. 1999;135:574580.
  • 26
    Wollenberg A, Regele D, Sharma S, et al. Topical tacrolimus treatment leads to profound alteration of the antigen presenting cells in lesions atopic dermatitis skin. J Invest Dermatol. 1996;107:468.
  • 27
    Homey B, Assman T, Vohar HW, et al. Topical FK506 suppress interleukin-12 and costimulatory molecular expression in vivo. J Invest Dermatol. 1997;109:454.
  • 28
    Panhans A, Bieber T. FK506 (tacrolimus) impairs the phenotypic and functional differentiation of human epidermal Langerhans cells. J Invest Dermatol. 1996;107:485.
  • 29
    De Paulis A, Stellato C, Cirillo R, et al. Antiinflammatory effects of FK506 on human skin mast cells. J Invest Dermatol. 1992;99:723728
  • 30
    Eberlein-Konig B, Ruzicka T, Michel G, et al. Modulation of histamine release in vitro by FK506 and interleukin-3 is determined by sequence of incubation. Arch Dermatol Res. 1997;289:606608.
  • 31
    Griffith JP, Kim JL, Kim EE, et al. X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex. Cell. 1995;82:507522.
  • 32
    Fung JJ, Alessiani M, Abu-Elmagd K, et al. Adverse effects associated with the use of FK 506. Transplant Proc. 1991;23:31053108.
  • 33
    Reitamo S, Wollenberg A, Schopf E, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol. 2000;136:9991006.
  • 34
    Sand C. Topical tacrolimus ointment may induce skin tags in treated patients. Acta Derm Venereol. 2003;83:317.
  • 35
    Bernard LA, Cunningham BB, Al-Suwaidan S, et al. A rosacea-like granulomatous eruption in a patient using tacrolimus ointment for atopic dermatitis. Arch Dermatol. 2003;139:229231.
  • 36
    Antille C, Saurat JH, Lubbe J. Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment. Arch Dermatol. 2004;140:457460.
  • 37
    Fricain JC, Sibaud V, Campana F, et al. Mucosal pigmentation after oral lichen planus treatment with topical tacrolimus. Dermatology. 2005;210:229232.
  • 38
    Siddaiah N, Erickson Q, Miller G, et al. Tacrolimus-induced tinea incognito. Cutis. 2004;73:237238.
  • 39
    Ahn BK, Kim BD, Lee SJ, et al. Molluscum contagiosum infection during the treatment of vitiligo with tacrolimus ointment. J Am Acad Dermatol. 2005;52:532533.
  • 40
    Lerbaek A, Agner T. Facial eruption of molluscum contagiosum during topical treatment of atopic dermatitis with tacrolimus. Br J Dermatol. 2004;150:12101211.
  • 41
    Wilson LM, Reid CM. Molluscum contagiosum in atopic dermatitis treated with 0.1%tacrolimus ointment. Australas J Dermatol. 2004;45:184185.
  • 42
    Narang T, Pahwa M, Kanwar JA, et al. Verruca vulgaris following treatment with tacrolimus ointment. Dermatology. 2006;213:254255.
  • 43
    The European FK506 Multicentre Psoriasis Study Group. Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. Arch Dermatol. 1996;132:419423
  • 44
    Nikolaidis N, Abu-Elmagd K, Thomson AW, et al. Metabolic effects of FK 506 in patient with severe psoriasis: short-term follow-up of seven cases. Transplant Proc. 1991;23:33253327.
  • 45
    Kawashima M, Nakagawa H, Ohtsuki M, et al. Tacrolimus concentrations in blood during topical treatment of atopic dermatitis. Lancet. 1996;348:12401241.
  • 46
    Ostovari N, Passeron T, Lacour JP, et al. Lack of efficacy of tacrolimus in the treatment of vitiligo in the absence of UV-B exposure. Arch Dermatol. 2006;142:252253.